Number of Monoclonal Antibody Products in Development Continues to Increase, According to Tufts Center for the Study of Drug Development
08 nov. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Nov 8, 2011) - Developers are steadily increasing the number of monoclonal antibody products -- known as mAbs -- for which they are initiating clinical studies, extending...
Drug Companies Are Using Innovative Partnerships to Spur Development, According to Tufts Center for the Study of Drug Development
06 oct. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Oct 6, 2011) - Responding to strong and growing pressure to reduce development times and increase the output of new medicines, drug companies are engaging in innovative...
Majority of Clinical Trial Protocols Are Amended, but One-Third of Those Changes Are Avoidable, According to Tufts Center for the Study of Drug Development
13 sept. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Sep 13, 2011) - Nearly 60 percent of all protocols used in clinical trials for new drugs are amended during the trial. Moreover, one-third of those changes could have been...
Growing Regulatory Requirements Worldwide Challenge Drug Developers, According to Tufts Center for the Study of Drug Development
09 août 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Aug 9, 2011) - As pharmaceutical and biopharmaceutical companies increase the number of clinical trials they conduct in emerging global markets, growing regulatory...
Lack of Clinically Useful Diagnostics Hinders Growth in Personalized Medicines, According to Tufts Center for the Study of Drug Development
19 juil. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jul 19, 2011) - Lack of evidence that links diagnostic tests to health outcomes has led payers in the United States to be skeptical about the clinical usefulness of those...
Biotech Drug Approvals in the U.S. Nearly Doubled in the Last Decade, According to Tufts Center for the Study of Drug Development
10 mai 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - May 10, 2011) - U.S. regulatory approvals for new biopharmaceuticals nearly doubled in the last decade, compared to the 1990s, according to the Tufts Center for the Study of...
Drug Developers Actively Improving Efficiency of Clinical Trials, According to Tufts Center for the Study of Drug Development
26 avr. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Apr 26, 2011) - Looking to improve the operational efficiency of clinical trials, drug developers are actively pursuing new strategies that include collaborating with...
U.S. Approvals of Supplemental Drug Indications Have Been Rising Steadily, According to Tufts Center for the Study of Drug Development
08 mars 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - March 8, 2011) - New or modified indication approvals for existing prescription drugs have steadily increased in the United States since the late 1990s, according to an...
Translational Science Expected to Play a Growing Role in Creating New Drugs, According to Tufts Center for the Study of Drug Development
27 janv. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 27, 2011) - To produce drug candidates at the pace needed to remain competitive, pharmaceutical and biotech companies increasingly are using translational science to...
U.S. Healthcare Stakeholders Uncertain About Benefits of Risk Evaluation Program, According to Tufts Center for the Study of Drug Development
12 janv. 2011 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - January 12, 2011) - Drug developers, healthcare providers, insurance companies, and others involved in the delivery of healthcare in the United States are uncertain about...